CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$3.13 USD
-0.17 (-5.15%)
Updated May 20, 2024 04:00 PM ET
After-Market: $3.10 -0.03 (-0.96%) 7:58 PM ET
5-Strong Sell of 5 5
F Value B Growth NA Momentum NA VGM
Price, Consensus and EPS Surprise
CASI 3.13 -0.17(-5.15%)
Will CASI be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CASI based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CASI
USANA Health Sciences (USNA) Q3 Earnings Miss Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates (Revised)
CASI: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProPhase Labs, Inc. (PRPH) Reports Q2 Loss, Lags Revenue Estimates
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Surpass Estimates
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
Other News for CASI
Casi Pharma spikes as FDA clears clinical trial for blood disorder therapy
CASI Pharmaceuticals Receives FDA Clearance On The Investigational New Drug (IND) Application For CID-103 In Immune Thrombocytopenia (ITP)
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Casi receives permission to proceed with CID-103 study from FDA
CASI Pharmaceuticals: A Buy Rating Amid Financial and Clinical Promise